Psoriasis Remedies - The Most Effective Psoriasis Treatment, Psoriasis cure
Psoriasis Remedies - The Most Effective Psoriasis Treatment, Psoriasis cure The five main types of psoriasis are plaque, guttate, inverse, pustular, and eryt...
By: Bala Guru
See original here:
Psoriasis Remedies - The Most Effective Psoriasis Treatment, Psoriasis cure - Video
Alternative Healing of Skin Cancer, Psoriasis, Vitiligo, Melanoma, Leukemia too. Illinois, Chicago
Alternative Healing of Skin Cancer, Psoriasis, Vitiligo, Melanoma, Leukemia too. Healing From Deadly Diseases, Real Healer and Real Results of His Treatment, Mujin Troi The path to the miracle...
By: The SunGates Center
See the original post here:
DERMATOLOGIE - Psoriasis : Quality Careet l #39;application MonPso
By: LEO Pharma France
More here:
DERMATOLOGIE - Psoriasis : Quality Careet l'application MonPso - Video
Psoriasis treatment with Healthy Skin Clinic
The natural psoriasis treatment developed by Healthy Skin Clinic is holistic and addresses the triggers plus the symptoms of psoriasis. Our psoriasis treatment program gives our clients access...
By: Vivienne Savill
Read more:
palmar psoriasis treated by Homeopathic medicines dr ak dwivedi
palmar psoriasis treated by dr ak dwivedi.
By: Dr AK Dwivedi
See original here:
palmar psoriasis treated by Homeopathic medicines dr ak dwivedi - Video
(PRWEB) December 30, 2014
Psoriasis: Targets and Therapy has published the original research Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: An ethnography study.
As corresponding author Mr Siva Narayanan says Our ethnography study is one of the first of its kind in the Psoriasis arena to uncover and describe subtle or less well-defined HRQoL concepts and highlight the voice of the patient and their perception of their disease. As such, we were able to highlight the issues such as patients self-isolation, relationships with their partner and family, self-consciousness and anxiety, and the extensive planning and daily routines that are required to cope with everyday life and avoid uncomfortable social situations. We also exposed cultural differences in this study, including differing expression of emotional impacts and (un)willingness/(in)ability to discuss psoriasis with others, which contributes to severe psychosocial burden.
Mr Narayanan continues We believe that the findings from our study could aid families, care givers and healthcare providers alike in recognizing the psoriasis disease burden (from patient perspective) and accordingly suggest coping techniques to improve patient HRQoL. Further, our results could inform development and/or refining of PRO instruments in psoriasis.
As Dr Uwe Wollina, Editor-in-Chief, explains There are very few investigations on psoriasis available. This paper tries to bridge this gap of knowledge.
Psoriasis: Targets and Therapy is an international, peer-reviewed, open access journal focusing on psoriasis, nail psoriasis, psoriatic arthritis and related conditions, identification of therapeutic targets and the optimal use of integrated treatment interventions to achieve improved outcomes and quality of life.
Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine.
Excerpt from:
Psoriasis Diet Diary Week Fourteen
This week has been amazing for healing. The speed at the moment is incredible. Today #39;s video also features a walk with Penny and my typical food shop. Merry ...
By: Jon Maddison
Continue reading here:
The Novartis headquarters in Basel, Switzerland.
ZURICH--Swiss pharmaceutical company Novartis AG said Friday that it won approval in Japan for a new psoriasis drug, the first country to give the treatment a green light for commercialization.
Novartis NOVN, -1.28% said secukinumab, marketed as Cosentyx, is approved in the country to treat psoriasis vulgaris and psoriatic arthritis in patients who dont respond to other medication.
The drug is seen by some analysts as a potential blockbuster, industry jargon for medicines that generate more than $1 billion in sales annually. Demand for new treatments for psoriasis and related diseases is high.
Psoriasis is a chronic disease that is characterized by thick and extensive skin lesions. It causes itching, scaling and pain. Psoriatic arthritis causes joint pain, stiffness and irreversible joint damage.
Cosentyx inhibits the action of a protein found in high concentrations in skin affected by psoriasis, Novartis said.
An expanded version of this report appears at WSJ.com.
More:
The Wall Street Journal: Novartis psoriasis drug approved in Japan
Swiss pharmaceutical giant Novartis AG (NVS: Quote) said Friday that Cosentyx has been approved in Japan for both psoriasis vulgaris and psoriatic arthritis, marking the first country approval for Cosentyx in the world. The approval also makes Cosentyx the first interleukin-17A or IL-17A inhibitor to receive regulatory approval in either of these indications in Japan.
Novartis said that the Japanese Ministry of Health, Labour and Welfare approved Cosentyx or secukinumab, formerly known as AIN457, for the treatment of both psoriasis vulgaris and psoriatic arthritis or PsA in adults who are not adequately responding to systemic therapies.
David Epstein, Division Head, Novartis Pharmaceuticals said, "We are pleased that Japan is the first country to approve Cosentyx for both psoriasis and psoriatic arthritis, providing an alternative treatment option for more than 400,000 Japanese citizens who are living with psoriasis, and those also living with psoriatic arthritis."
Psoriasis is a chronic immune-mediated disease characterized by thick and extensive skin lesions, called plaques. The plaques are known to cause itching, scaling and pain, and is associated with significant impairment of physical and psychological quality of life.
Closely linked with psoriasis, PsA causes joint pain and stiffness, skin and nail psoriasis, swollen toes and fingers, persistent painful tendonitis and irreversible joint damage. Psoriatic arthritis affects 30 percent of psoriasis patients globally and can cause irreversible joint damage.
Cosentyx works by inhibiting the action of IL-17A, a protein that is found in high concentrations in skin affected by psoriasis and central to the development of inflammatory diseases, including psoriasis and PsA.
Novartis noted that many patients do not respond to or tolerate current psoriasis or psoriatic arthritis treatments, indicating an unmet need for new therapies for these diseases. The company noted that with today's approval, these patients now have a new treatment option that effectively treats both diseases.
The Japanese approval was based on the safety and efficacy results from more than 10 Phase II and Phase III studies, which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.
It was also supported by two pivotal Phase III studies, FUTURE 1 and FUTURE 2, involving more than 1,000 patients with PsA. In all studies, Cosentyx demonstrated a favorable safety profile, with similar incidence and severity of adverse events between Cosentyx treatment arms of 300 mg and 150 mg.
Novartis obtained a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP in November 2014, recommending Cosentyx as a first-line treatment of moderate-to-severe psoriasis patients in Europe.
View original post here:
GENEVA Swiss pharmaceutical giant Novartis said Friday it has won approval to market its Cosentyx psoriasis treatment in Japan, making it the first country to authorize commercialization of the drug.
The Japanese decision allows Novartis to sell secukinumab, sold under the name Cosentyx, to adult patients suffering psoriasis vulgaris and psoriatic arthritis, and who arent responding to other medication.
The drug is considered by experts to have potentially enormous market value of between $1 billion and $2.5 billion annually. Its estimated 3 percent of the worlds population or over 125 million people suffer from some form of psoriasis, including over 400,000 in Japan alone.
Psoriasis vulgaris is a skin disease provoking thick, itchy lesions, while the articular variant causes stiffness and pain in joints.
Novartis said in a statement that during clinical testing of the drug, 70 percent of patients experienced improvement or complete clearing of their psoriasis symptoms.
Approval in Japan follows the recommendation by European drug regulators in November that Cosentyx be approved for sale as a first-line treatment for psoriasis.
Similarly, the U.S. Food and Drug Administration is expected to approve the medication in early 2015 after its panel issued a similarly positive recommendation in October.
Novartis says Cosentyx is a human monoclonal antibody that neutralizes a protein that is present in highly concentrated levels in psoriasis patients.
View post:
By RTT News, December 26, 2014, 07:22:00 AM EDT
(RTTNews.com) - Swiss pharmaceutical giant Novartis AG ( NVS ) said Friday that Cosentyx has been approved in Japan for both psoriasis vulgaris and psoriatic arthritis, marking the first country approval for Cosentyx in the world. The approval also makes Cosentyx the first interleukin-17A or IL-17A inhibitor to receive regulatory approval in either of these indications in Japan.
Novartis said that the Japanese Ministry of Health, Labour and Welfare approved Cosentyx or secukinumab, formerly known as AIN457, for the treatment of both psoriasis vulgaris and psoriatic arthritis or PsA in adults who are not adequately responding to systemic therapies.
David Epstein, Division Head, Novartis Pharmaceuticals said, "We are pleased that Japan is the first country to approve Cosentyx for both psoriasis and psoriatic arthritis, providing an alternative treatment option for more than 400,000 Japanese citizens who are living with psoriasis, and those also living with psoriatic arthritis."
Psoriasis is a chronic immune-mediated disease characterized by thick and extensive skin lesions, called plaques. The plaques are known to cause itching, scaling and pain, and is associated with significant impairment of physical and psychological quality of life.
Closely linked with psoriasis, PsA causes joint pain and stiffness, skin and nail psoriasis, swollen toes and fingers, persistent painful tendonitis and irreversible joint damage. Psoriatic arthritis affects 30 percent of psoriasis patients globally and can cause irreversible joint damage.
Cosentyx works by inhibiting the action of IL-17A, a protein that is found in high concentrations in skin affected by psoriasis and central to the development of inflammatory diseases, including psoriasis and PsA.
Novartis noted that many patients do not respond to or tolerate current psoriasis or psoriatic arthritis treatments, indicating an unmet need for new therapies for these diseases. The company noted that with today's approval, these patients now have a new treatment option that effectively treats both diseases.
The Japanese approval was based on the safety and efficacy results from more than 10 Phase II and Phase III studies, which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.
It was also supported by two pivotal Phase III studies, FUTURE 1 and FUTURE 2, involving more than 1,000 patients with PsA. In all studies, Cosentyx demonstrated a favorable safety profile, with similar incidence and severity of adverse events between Cosentyx treatment arms of 300 mg and 150 mg.
Read the original:
Novartis Drug Cosentyx Approved In Japan For Psoriasis And Psoriatic Arthritis
By RTT News, December 26, 2014, 02:39:00 AM EDT
(RTTNews.com) - Novartis ( NVS ) said Friday that the Japanese Ministry of Health, Labour and Welfare or MHLW approved Cosentyx (secukinumab, formerly known as AIN457), for the treatment of both psoriasis vulgaris and psoriatic arthritis or PsA in adults who are not adequately responding to systemic therapies (except for biologics).
The company noted that the approval marks the first country approval for Cosentyx in the world and makes it the first interleukin-17A or IL-17A inhibitor to receive regulatory approval in either of these indications in Japan.
The approval was based on the safety and efficacy results from more than 10 Phase II and Phase III studies which included nearly 4,000 patients with moderate-to-severe plaque psoriasis and supported by two pivotal Phase III studies, FUTURE 1 and FUTURE 2, involving more than 1,000 patients with PsA.
In all studies, Cosentyx demonstrated a favorable safety profile, with similar incidence and severity of adverse events or AEs between Cosentyx treatment arms (300 mg and 150 mg).
Cosentyx works by inhibiting the action of IL-17A, a protein that is found in high concentrations in skin affected by psoriasis and central to the development of inflammatory diseases, including psoriasis and PsA. As approximately 30% of psoriasis patients are also affected by PsA globally.
Psoriatic arthritis is a debilitating, long-lasting inflammatory disease linked with significant disability, poor quality of life and reduced life expectancy.
The company said that the US Food and Drug Administration approval in the same indication is anticipated in early 2015 following the unanimous recommendation of approval in October 2014 from the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US FDA.
For comments and feedback: contact editorial@rttnews.com
Read more from the original source:
Novartis'' Cosentyx Approved In Japan For Both Psoriasis And Psoriatic Arthritis
Psoriasis Revolution | Psoriasis Revolution Review
http://tinyurl.com/mty6gvt Psoriasis Revolution Psoriasis Revolution Review Psoriasis Revolution Download Psoriasis Revolution PDF Psoriasis Revolution Disco...
By: Pengen Nangis
See the rest here:
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Headline and subhead of release should reference "Markers" instead of "Makers."
The corrected release reads:
PROVECTUS BIOPHARMACEUTICALS PROTOCOL FOR PHASE 2 STUDY OF MECHANISM OF ACTION OF PH-10 ON IMMUNOLOGIC MARKERS OF PSORIASIS NOW AVAILABLE ONLINE
Study Will Assess Effects Of PH-10 On Immunologic Markers of Psoriasis
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"), announced today that the protocol for its phase 2 study of the mechanism of action of PH-10 in psoriasis is now available on ClinicalTrials.gov, Identifier NCT02322086: https://www.clinicaltrials.gov/ct2/show/NCT02322086.
The protocol states that the multicenter study is designed to assess treated psoriatic plaque for changes in immunologic, structural and hyperproliferative state and for any evidence of cellular atypia when treated with PH-10 and to correlate observed changes in the skin with clinical response to treatment. These assessments are expected to advance the understanding of the mechanism of action of PH-10 in psoriasis and other inflammatory dermatoses, such as atopic dermatitis, and further substantiate the safety profile of the agent.
The study will enroll up to 30 subjects with mild to moderate plaque psoriasis. Subjects will apply vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their psoriatic plaques. Biopsies of one plaque will be collected at baseline and immediately after completion of vehicle application and PH-10 application. This will allow data from each subject to serve as an internal control for assessment of clinical and cellular response to PH-10. Biopsy specimens will be assessed for changes in epidermal hyperplasia (i.e., disordered condition of the skin creating thickening and scaling); infiltration with immune cells; and molecular markers of inflammation. Correlation of clinical response to these cellular and molecular changes will be performed at the plaque level using Psoriasis Severity Index (PSI) assessment data.
Safety will be assessed by monitoring the frequency, duration, severity and attribution of clinical adverse events; evaluating changes in laboratory values and vital signs; and by correlation of clinical adverse events with observed histopathologic and immunohistopathologic changes in the skin.
Eric Wachter, PhD, Chief Technology Officer of Provectus, noted, By capturing data at the clinical and cellular level, this study should allow us to establish how PH-10 affects psoriatic plaque and other similar inflammatory diseases of the skin, and to relate the safety profile from earlier studies to such effects. We believe that understanding these effects with this level of detail will allow us to properly position PH-10 within the competitive landscape and should provide crucial safety data to support extended dosing.
Dr. Wachter added, We expect this effort to provide a comparable level of understanding of the effects of PH-10 in diseased skin to the keen insight we have gained through our clinical and nonclinical mechanism studies of PV-10, Provectus novel investigational cancer drug, in melanoma and other cancers. Because there are no good model systems for psoriasis, we believe this study affords a critical opportunity to link the clinical effects we have observed to changes in well established immunologic drivers of the disease.
See the rest here:
You #39;ve Got This Psoriasis: Brian Krans from Oakland, CA
You #39;ve Got This supports the psoriasis community and gives hope and inspiration to newly diagnosed patients. Psoriasis patients submit videos sharing their l...
By: Healthline
Read the rest here:
You've Got This Psoriasis: Brian Krans from Oakland, CA - Video
Psoriasis Diet Diary Week Thirteen
Day 95 of me using diet to solve my psoriasis. I have stopped moisturising this week as I want to leave my skin un-clogged and allow my body to maintain its ...
By: Jon Maddison
Read more:
Homeopathic Treatment for Psoriasis | Nucleus Homeopathy | Doctors Talk
Doctors Talk is an exclusive program by CVR Health TV in which a specialist will discuss about different health problems and suggest remedies. Watch CVR Health, the 24/7 health channel with...
By: CVR Health TV
See more here:
Homeopathic Treatment for Psoriasis | Nucleus Homeopathy | Doctors Talk - Video
Our Psoriasis Cure
One Families Journey To Wellness....Through Food.
By: Eric Lindsell
Go here to read the rest:
2014: vlog/psoriasis/health
This video is a lot different from my other uploads. It #39;s now been a year of me battling Psoriasis, and I just wanted to share what it #39;s been like because I haven #39;t really talked about it with...
By: AlyssaRevolution
Read this article: